fms-Like Tyrosine Kinase 3
"fms-Like Tyrosine Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Descriptor ID |
D051941
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.020 D12.776.543.750.630.020 D12.776.624.664.700.114
|
Concept/Terms |
fms-Like Tyrosine Kinase 3- fms-Like Tyrosine Kinase 3
- fms Like Tyrosine Kinase 3
- Fetal Liver Kinase-2
- Fetal Liver Kinase 2
- Fetal Liver Kinase-3
- Fetal Liver Kinase 3
- CD135 Antigens
- Antigens, CD135
- CD135 Antigen
- Antigen, CD135
- Stem Cell Tyrosine Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "fms-Like Tyrosine Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "fms-Like Tyrosine Kinase 3".
This graph shows the total number of publications written about "fms-Like Tyrosine Kinase 3" by people in this website by year, and whether "fms-Like Tyrosine Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 0 | 2 | 2 | 2006 | 1 | 0 | 1 | 2007 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2014 | 1 | 1 | 2 | 2015 | 1 | 0 | 1 | 2016 | 1 | 2 | 3 | 2017 | 3 | 0 | 3 | 2019 | 2 | 2 | 4 | 2020 | 0 | 1 | 1 | 2021 | 2 | 0 | 2 | 2022 | 0 | 1 | 1 | 2023 | 0 | 2 | 2 | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles.
-
Frisch A, Ganzel C, Ofran Y, Krayem B, Haran A, Vainstein V, Aumann S, Even-Zohar NG, Nachmias B. Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission. Eur J Haematol. 2025 Apr; 114(4):641-649.
-
Lee JS, Wagner CB, Prelewicz S, Kurish HP, Walchack R, Cenin DA, Patel S, Lo M, Schlafer D, Li BKT, Donald Harvey Iii R, Wasef B, Ying J, Kovacsovics T. Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia. Haematologica. 2023 12 01; 108(12):3460-3463.
-
Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023 02 01; 108(2):457-471.
-
Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, Jordan CT, Kieft JS, DeGregori J. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. Elife. 2022 10 19; 11.
-
Koschade SE, Klann K, Shaid S, Vick B, Stratmann JA, Th?lken M, Meyer LM, Nguyen TD, Campe J, Moser LM, Hock S, Baker F, Meyer CT, Wempe F, Serve H, Ullrich E, Jeremias I, M?nch C, Brandts CH. Translatome proteomics identifies autophagy as a resistance mechanism to on-target FLT3 inhibitors in acute myeloid leukemia. Leukemia. 2022 10; 36(10):2396-2407.
-
Droho S, Perlman H, Lavine JA. Dendritic cells play no significant role in the laser-induced choroidal neovascularization model. Sci Rep. 2021 08 26; 11(1):17254.
-
Brown PA, Kairalla JA, Hilden JM, Dreyer ZE, Carroll AJ, Heerema NA, Wang C, Devidas M, Gore L, Salzer WL, Winick NJ, Carroll WL, Raetz EA, Borowitz MJ, Small D, Loh ML, Hunger SP. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 05; 35(5):1279-1290.
-
Tufa DM, Shank T, Yingst AM, Trahan GD, Shim S, Lake J, Woods R, Jones K, Verneris MR. Prolactin Acts on Myeloid Progenitors to Modulate SMAD7 Expression and Enhance Hematopoietic Stem Cell Differentiation into the NK Cell Lineage. Sci Rep. 2020 04 14; 10(1):6335.
-
McMahon CM, Perl AE. Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia. Expert Rev Clin Pharmacol. 2019 Sep; 12(9):841-849.
-
McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD, Carroll M, Perl AE. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019 05 28; 3(10):1581-1585.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|